Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Phase 2 Trial of a Multivalent WT1 Peptide Vaccine (Galinpepimut-S) in Acute Myeloid Leukemia.

Peter G. Maslak,Tao Dao,Yvette Bernal,Suzanne M. Chanel,Rong Zhang,Mark Frattini,Todd Rosenblat,Joseph G. Jurcic,Renier J. Brentjens,Maria E. Arcila,Raajit Rampal,Jae H. Park,Dan Douer,Laura Katz,Nicholas Sarlis,Martin S. Tallman,David A. Scheinberg

Blood Advances（2018）

Cited 0|Views6
No score
Abstract
Key Points A heteroclitic WT1 peptide vaccine is well tolerated and induces immunologic responses in most acute myeloid leukemia patients post-CR1. Median overall survival for the group of patients vaccinated was not reached but is poised to reach or exceed 67.6 months.
More
Translated text
Key words
WT1 Gene
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined